World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website https://wjon.elmerpub.com

Original Article

Volume 16, Number 4, August 2025, pages 331-341

Efficacy of Infliximab Versus Vedolizumab in the Management of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review and Meta-Analysis

Figures

↓  Figure 1. PRISMA flowchart. PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Figure 1.
↓  Figure 2. Risk of bias assessment of selected studies.
Figure 2.
↓  Figure 3. Recurrence of colitis: vedolizumab vs. infliximab. OR: odds ratio; CI: confidence interval.
Figure 3.
↓  Figure 4. Median dose of steroid exposure: vedolizumab vs. infliximab. MD: mean difference; CI: confidence interval.
Figure 4.
↓  Figure 5. Remission of colitis: vedolizumab vs. infliximab. OR: odds ratio; CI: confidence interval.
Figure 5.
↓  Figure 6. Difference in mean SIT doses (vedolizumab vs. infliximab). SD: standard deviation; MD: mean difference; CI: confidence interval.
Figure 6.
↓  Figure 7. Mean doses of vedolizumab. SD: standard deviation; MRAW: raw mean score; CI: confidence interval.
Figure 7.
↓  Figure 8. Mean doses of infliximab. SIT: selective immunosuppressive therapy; SD: standard deviation; CI: confidence interval; MRAW: raw mean score.
Figure 8.

Tables

↓  Table 1. Characteristics of Studies Included
 
Study Male sex (n) Median age (years) White race (n) Total patients who received SIT (n) Year Country Study design VDZ only (n) IFX only (n) IFX f/b VDZ (n) VDZ f/b IFX (n) Types of cancer (n)
RC: retrospective cohort; N/A: not available; VDZ: vedolizumab; IFX: infliximab; f/b: followed by; GU: genitourinary; GI: gastrointestinal; RCC: renal cell carcinoma.
Zou et al, 2021 [18] 118 64 169 184 2021 USA RC 62 94 28 0 Melanoma: 54
GU cancer: 49
Lung cancer: 26
Others: 27
Stage 3: 26
Stage 4: 130
Abu-Sbeih et al, 2019 [19] 66 60 76 84 2019 USA RC 32 46 4 2 Melanoma: 40
GU cancer: 28
Thoracic, head and neck cancer: 11
Stage 4: 72
Badran et al, 2023 [20] 42 61.3 N/A 77 2023 USA RC 44 33 0 0 Melanoma: 35
GU cancer: 14
Lung/head/neck cancer: 15
GI cancer: 6
Endocrine: 1
Other: 6
Stage: N/A
Machado et al, 2023 [21] 105 63 139 156 2023 USA RC 59 81 16 0 Melanoma: 70
GU cancer: 53
Thoracic/head and neck cancer: 20
GI cancer: 6
Hematological: 3
Other: 5
Stage 3: 22
Stage 4: 134
Joseph et al, 2024 [22] 29 65 55 55 2024 USA RC 22 33 0 0 Melanoma: 28
Non-melanoma: 27
Metastatic cancer: 29
Metastatic: 29
Abu-Sbeih et al, 2018 [23] 20 63 N/A 28 2018 USA RC 19 9 9 0 Melanoma: 7
RCC: 4
Prostate carcinoma: 4
Urothelial cancer: 3
Other solid tumors: 10
Stage 3: 6
Stage 4: 22

 

↓  Table 2. Number of Patients Receiving Particular ICI and Number of Doses of SIT Administered
 
Study Outcomes ICI type SIT
Anti-CTLA-4 (n) Combined (n) Anti PD (L)-1 (n) VDZ (n) IFX (n)
aCTLA-4 alone or in combination. ICI: immune checkpoint inhibitor; CTLA-4: cytotoxic T-lymphocyte-associated antigen 4; VDZ: vedolizumab; IFX: infliximab; SIT: selective immunosuppressive therapy; SD: standard deviation; IQR: interquartile range.
Zou et al, 2021 [18] Remission, recurrence, median duration of steroid exposure, mean doses of SIT 23 55 78 3 (SD: 2) 2 (SD: 1)
Abu-Sbeih et al, 2019 [19] Recurrence, mean doses of SIT 21 30 33 3 (IQR: 1 - 6) 1 (IQR: 1 - 3)
Badran et al, 2023 [20] Recurrence 3 42 32 N/A N/A
Machado et al, 2023 [21] Median duration of steroid exposure, mean doses of SIT 26 62 68 3 (IQR: 2 - 4) 1 (IQR: 1 - 2)
Joseph et al, 2024 [22] Recurrence, median duration of steroid exposure, mean doses of SIT 20a 35 1 (IQR: 1 - 2) 1 (IQR: 1 - 2)
Abu-Sbeih et al, 2018 [23] Remission, mean doses of SIT 8 8 12 3 (IQR: 1 - 4) 2 (IQR: 1 - 3)